INmune Bio Impairs $16.5M Asset, Completes Prostate Cancer Trial Under Budget
INmune Bio posted a $45.9 million net loss and $20.7 million in R&D expenses for 2025, including a full $16.5 million impairment of its intangible asset after Phase 2 Alzheimer trial failure. It completed a prostate cancer Phase 2 trial under budget and holds $24.8 million cash through Q1 2027.
1. Q4 2025 Financial Results
INmune Bio reported a net loss of $45.9 million for 2025, with R&D expenses of $20.7 million and G&A expenses of $10.3 million. The company held $24.8 million in cash and cash equivalents, sufficient to fund operations through Q1 2027.
2. Intangible Asset Impairment
The company recorded a full impairment of its intangible asset worth $16.5 million following failure to meet the clinical endpoint in its Alzheimer’s Phase 2 trial. This write-down reflects the program’s discontinued potential after trial results.
3. Prostate Cancer Trial Success
INmune Bio completed its Phase 2 metastatic castration-resistant prostate cancer trial ahead of schedule and under budget, achieving the primary endpoint and two of three secondary endpoints. This success positions XPro for late-stage development and potential partnerships.
4. Regulatory and Strategic Outlook
Regulatory preparations include creating a new master seed stock to meet FDA requirements for US donor testing and filing an MAA for CORDStrom in the UK by summer 2026. The company is engaging potential pharma partners to support late-stage development and funding strategies.